Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial-Reference-Cited by-同舟云学术

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

Published:2015-03-14 Issue:1 Volume:15 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Brodowicz Thomas,Liegl-Atzwager Bernadette,Tresch Emmanuelle,Taieb Sophie,Kramar Andrew,Gruenwald Viktor,Vanseymortier Marie,Clisant Stéphanie,Blay Jean-Yves,Le Cesne Axel,Penel Nicolas

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/s12885-015-1143-y/fulltext.html

Reference20 articles.

1. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10:833–41.

2. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Hohenberger P, Blay JY. Testing new regimes in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2011;22:1266–72.

3. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188–96.

4. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–63.

5. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27:3126–32.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Treatment of Soft-Tissue Sarcoma;Journal of Personalized Medicine;2023-04-26

2. Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study;Cancers;2020-12-12

The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution

;Cancer Management and Research;2020-07

4. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113);International Journal of Gynecologic Cancer;2020-06-15

5. Mullerian adenosarcomas of the uterine cervix with sarcomatous overgrowth;Current Problems in Cancer;2019-08